H.C. Wainwright raised the firm’s price target on Context Therapeutics (CNTX) to $5 from $4 and keeps a Buy rating on the shares following the Q3 report. The company noted a confirmed partial response in Cohort 3 for a patient with platinum resistant ovarian cancer, which is a “highly positive sign of activity,” the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Positive Outlook for Context Therapeutics: Promising Developments in CTIM-76 Study Justify Buy Rating
- Context Therapeutics Reports Improved Quarterly Results
- Context Therapeutics reports Q3 EPS (10c), consensus (9c)
- Context Therapeutics Reports Q3 2025 Financial Results
- Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study